Egrifta

Egrifta Uses, Dosage, Side Effects, Food Interaction and all others data.

Egrifta is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.

Egrifta stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels.

Trade Name Egrifta
Availability Prescription only
Generic Tesamorelin
Tesamorelin Other Names GHRH(1-44), Tesamorelin
Related Drugs Egrifta, metreleptin, Myalept
Weight 1mg, 2mg,
Type Subcutaneous powder for injection
Formula C216H360N72O63S
Weight Average: 5005.76
Monoisotopic: 5002.690032114
Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country United States,
Last Updated: September 19, 2023 at 7:00 am
Egrifta
Egrifta

Uses

Egrifta is a growth hormone releasing factor (GRF) analog used to reduce excessive abdominal fat in HIV patients who have developed lipodystrophy.

Egrifta acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Egrifta is also used to associated treatment for these conditions: Lipodystrophies

How Egrifta works

By acting on the pituitary cells in the brain, tesamorelin stimulates production and release of the endogenous hormone (hGRF). Egrifta therapy predisposes the patient to glucose intolerance and can also increase the risk of type 2 diabetes, so the drug is contraindicated in pregnancy.

Toxicity

Diarrhea, congestive heart failure, peripheral neuropathy, and loss of mobility were the four serious adverse events reported during the clinical studies

Food Interaction

No interactions found.

Volume of Distribution

9.4±3.1 L/kg in healthy subjects. 10.5±6.1 L/kg in HIV-infected patients.

Elimination Route

The absolute bioavailability was determined to be less than 4% in healthy adult subjects following a 2 mg subcutaneous dose.

Half Life

26 and 38 minutes in healthy subjects and HIV-infected patients, respectively.

Innovators Monograph

You find simplified version here Egrifta

*** Taking medicines without doctor's advice can cause long-term problems.
Share